Bolt Biotherapeutics (BOLT, Financial) saw a significant stock price increase of 6.19%. The stock is currently priced at $0.669, with a trading volume of 31,574 shares, a turnover rate of 0.08%, and a price fluctuation of 3.97%.
Recent financial reports reveal that BOLT achieved a revenue of $1.28 million, but suffered a net loss of $21.20 million, resulting in an earnings per share (EPS) of -$0.56 and a gross profit of $818,000. The price-to-earnings ratio is currently -0.38. Analysts from four institutions unanimously recommend holding the stock, with no buy or sell advice issued.
In the broader biotechnology sector, which experienced a slight decline of 0.14%, several stocks have shown notable performance. 180 Life Sciences Corp. and Korro Bio Inc. saw significant gains, while 180 Life Sciences Corp., Quoin Pharmaceuticals Ltd, and Biodexa Pharmaceuticals Plc exhibited high trading activity. The turnover rates for these stocks were 7419.39%, 1901.62%, and 1170.06%, respectively. Additionally, the stocks of 180 Life Sciences Corp., Quoin Pharmaceuticals Ltd, and others experienced large price swings.
Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing tumor-targeted therapies that leverage the innate and adaptive immune systems. Its pipeline includes candidates like BDC-1001, BDC-3042, and Next-Gen ISAC, based on its proprietary Boltbody ISAC platform technology that combines tumor-targeting antibodies with immune-stimulating linker-payloads.
